Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Q2 2025 Management View CEO Christopher C. Gibson emphasized the integration of Exscientia's technology into Recursion OS 2.0, highlighting the company's end-to-end platform capabilities from target ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $6.12 / share. This is a decrease of 10.64% from the prior estimate of $6.85 dated April 25, 2026.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 ...